CRISPR BY DESIGN Trademark

Trademark Overview

On Tuesday, March 23, 2021, a trademark application was filed for CRISPR BY DESIGN with the United States Patent and Trademark Office. The USPTO has given the CRISPR BY DESIGN trademark a serial number of 90981354. The federal status of this trademark filing is REGISTERED as of Tuesday, February 11, 2025. This trademark is owned by Scribe Therapeutics Inc.. The CRISPR BY DESIGN trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, diagnostic and therapeutic products and services; design and development of engineered cells for use in scientific research and drug discovery and development; Providing medical research and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering
crispr by design

General Information

Serial Number90981354
Word MarkCRISPR BY DESIGN
Filing DateTuesday, March 23, 2021
Status700 - REGISTERED
Status DateTuesday, February 11, 2025
Registration Number7689563
Registration DateTuesday, February 11, 2025
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 21, 2022

Trademark Statements

NOT AVAILABLE"CRISPR"
Goods and ServicesScientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations, diagnostic and therapeutic products and services; design and development of engineered cells for use in scientific research and drug discovery and development; Providing medical research and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, June 28, 2021
Primary Code042
First Use Anywhere DateThursday, December 31, 2020
First Use In Commerce DateThursday, December 31, 2020

Trademark Owner History

Party NameScribe Therapeutics Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressAlameda, CA 94501
Party NameScribe Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAlameda, CA 94501
Party NameScribe Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAlameda, CA 94501

Trademark Events

Event DateEvent Description
Thursday, October 28, 2021NON-FINAL ACTION WRITTEN
Thursday, October 28, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 26, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 26, 2021NEW APPLICATION ENTERED
Tuesday, April 26, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 28, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, October 27, 2021ASSIGNED TO EXAMINER
Tuesday, April 26, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 28, 2021NON-FINAL ACTION E-MAILED
Tuesday, June 21, 2022PUBLISHED FOR OPPOSITION
Tuesday, June 21, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 16, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 8, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, February 8, 2023SOU EXTENSION 1 FILED
Friday, February 10, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 10, 2023SOU EXTENSION 2 GRANTED
Thursday, August 10, 2023SOU TEAS EXTENSION RECEIVED
Thursday, August 10, 2023SOU EXTENSION 2 FILED
Saturday, August 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 19, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 1, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 8, 2023SOU EXTENSION 1 GRANTED
Thursday, February 8, 2024SOU EXTENSION 3 FILED
Thursday, February 8, 2024SOU EXTENSION 3 GRANTED
Thursday, February 8, 2024SOU TEAS EXTENSION RECEIVED
Friday, February 9, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 14, 2024SOU EXTENSION 4 FILED
Wednesday, August 14, 2024SOU TEAS EXTENSION RECEIVED
Monday, August 19, 2024DIVISIONAL REQUEST RECEIVED
Monday, August 19, 2024USE AMENDMENT FILED
Monday, August 19, 2024TEAS REQUEST TO DIVIDE RECEIVED
Monday, August 19, 2024TEAS STATEMENT OF USE RECEIVED
Wednesday, October 23, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, November 18, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, December 16, 2024STATEMENT OF USE PROCESSING COMPLETE
Monday, December 16, 2024DIVISIONAL PROCESSING COMPLETE
Monday, December 16, 2024SOU EXTENSION 4 GRANTED
Monday, December 16, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, November 22, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, January 21, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, January 21, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, February 11, 2025REGISTERED-PRINCIPAL REGISTER
Tuesday, February 11, 2025NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

design crispr gene research modulation transcriptional therapy genetic engineering editing genome development